GLPwatch
Papers (10404)
Page 99 of 174, ranked by citation count.
- A Diabetic Patient Complicated With Pancreatic Cancer After Using Liraglutide: A Case Report.
- Exendin-4 improves cerebral ischemia by relaxing microvessels, rapidly increasing cerebral blood flow after reperfusion.
- The protective roles of liraglutide on Kawasaki disease via AMPK/mTOR/NF-κB pathway.
- IDegLira for the real-world treatment of type 2 diabetes in Italy. Final results from the REX observational study.
- Exendin-4 inhibits small intestinal glucose sensing and absorption through repression of T1R2/T1R3 sweet taste receptor signalling in streptozotocin diabetic mice.
- GLP-1 receptor agonist effects on normal and neoplastic pancreata.
- Pituitary Adenlylate Cyclase Activating Peptide Protects Adult Neural Stem Cells from a Hypoglycaemic milieu.
- Exendin‑4 reverses endothelial dysfunction in mice fed a high‑cholesterol diet by a GTP cyclohydrolase‑1/tetrahydrobiopterin pathway.
- Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.
- STEPping down diuretic therapy with semaglutide in obesity-related heart failure with preserved ejection fraction: decongestion or disease modification?
- Letter to Editor. Re "de Leeuw SP, et al. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK Positive Lung Cancer," Semaglutide a Potential Treatment for Serious Weight Gain From ALK Tyrosine Kinase Inhibitors?
- Effectiveness of Adjuvant Semaglutide Following Bariatric Metabolic Surgery.
- Energy loss via urine and faeces--a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight.
- Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.
- Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry!
- Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes-Interventional Study.
- Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months.
- Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists.
- Medicines for long-term obesity management.
- Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis.
- Real-world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting.
- Weight loss medication prescription prevalence in the active component, 2018-2023.
- Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial.
- Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis.
- Liraglutide Attenuates Restenosis After Vascular Injury in Rabbits With Diabetes Via the TGF-β/Smad3 Signaling Pathway.
- Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide.
- Truncated Glucagon-like Peptide-1 and Exendin-4 α-Conotoxin pl14a Peptide Chimeras Maintain Potency and α-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro.
- Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update.
- Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.
- GLP-1 receptor agonists, CKD, and eGFR trajectory.
- Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.
- Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature.
- Lixisenatide: A New Option for Managing Type 2 Diabetes.
- Tirzepatide Improves Early Dumping Syndrome and Glucose Nadir in Postbariatric Hypoglycemia After Sleeve Gastrectomy.
- GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond - New Insights 2015.
- Exendin-4 impairs the autophagic flux to induce apoptosis in pancreatic acinar AR42J cells by down-regulating LAMP-2.
- Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy.
- Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis
- Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration.
- Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.
- Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
- VMP1-related autophagy induced by a fructose-rich diet in β-cells: its prevention by incretins.
- Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study.
- Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis.
- The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
- Tirzepatide: A New Generation Therapeutic for Diabetes Type 2.
- Liraglutide preserves intracellular calcium handling in isolated murine myocytes exposed to oxidative stress.
- Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m<sup>2</sup> in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.
- Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.
- 18F-Labelled exendin to image GLP-1 receptor-expressing tissues: from niche to blockbuster?
- Evaluating the effect of Semaglutide as add-on therapy on glycemic control and continuous glucose monitoring outcomes in adults with type 1 diabetes: A two-year real-world data study.
- Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review.
- Liraglutide treatment is associated with progression of coronary artery fibrous plaque: a prospective 1-year follow-up study in asymptomatic patients with type 2 diabetes.
- Comparison of the Effects of Liraglutide on Islet Graft Survival Between Local and Systemic Delivery.
- New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
- Glucagon-like peptide-1 analog, liraglutide, regulates Sertoli cell energy metabolism.
- A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena.
- Efficacy and Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis.
- Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis.
- Turning fat into muscle: can this be an alternative to anti-obesity drugs such as semaglutide?